Paul Hanona, MD

Paul Hanona, MD, is the chief Hematology Oncology Fellow at Beaumont Health

Articles by Paul Hanona, MD

Chandler Park, MD, medical oncologist, Norton Cancer Institute; Paul Hanona, MD, content creator, @doctordiscover

Social Media Expands Access to Practical Public Health Education: With Chandler Park, MD; and Paul Hanona, MD

ByChandler Park, MD, MSc, FACP,Paul Hanona, MD

May 26th 2025

Drs Park and Hanona discuss the ways that public health content creation offers practical advice about a variety of topics but may also spark debate.

Chandler Park, MD, medical oncologist, Norton Cancer Institute; Paul Hanona, MD, chief Hematology Oncology Fellow, Beaumont Health

Motivation and Consistency Are Key to Building a Successful Oncology Educational Platform: With Chandler Park, MD; and Paul Hanona, MD

ByChandler Park, MD, MSc, FACP,Paul Hanona, MD

April 21st 2025

In this episode, Drs Park and Hanona give advice to up-and-coming oncology content creators.

Social Media Unlocks New Avenues for Expanding Access to Oncology Education: With Chandler Park, MD; and Paul Hanona, MD

ByChandler Park, MD, MSc, FACP,Paul Hanona, MD

April 16th 2025

Drs Park and Hanona discuss the role of social media in educating patients and oncologists about treatment advances and novel cancer screening methods.

Paul Hanona, MD

Articles by Paul Hanona, MD

Social Media Expands Access to Practical Public Health Education: With Chandler Park, MD; and Paul Hanona, MD

Motivation and Consistency Are Key to Building a Successful Oncology Educational Platform: With Chandler Park, MD; and Paul Hanona, MD

Social Media Unlocks New Avenues for Expanding Access to Oncology Education: With Chandler Park, MD; and Paul Hanona, MD

Latest Updated Articles

Trending on OncLive

FDA Approves Daratumumab and Hyaluronidase Plus VRd for Newly Diagnosed Multiple Myeloma

PD-L1 Expression Is More Predictive of Response to Pembrolizumab on Metastatic Sites in High-Grade Serous Ovarian Cancer

NP-G1-044 Receives FDA Orphan Drug Designation for Pancreatic Cancer

Meta-Analysis Characterizes Nivolumab/Ipilimumab Hyperprogression in Renal Medullary Carcinoma

Dr Braunstein on the FDA Approval of Subcutaneous Daratumumab With VRd For Newly Diagnosed Multiple Myeloma